Supplementary information

Extracellular vesicles from CLEC2-activated platelets enhance dengue virus-induced lethality via CLEC5A/TLR2

Sung et al.





Supplementary Figure 1. Immunofluorescence staining of NET structure and expression levels of CLEC5A, CLEC2 in human neutrophils and platelets. (**a**) DNA, histone, and MPO were detected by Hoechst 33342 (blue), anti-histone antibody (green), and anti-MPO antibody (red), respectively. Scale bar: 10 μ m. (**b**) Expression level of CLEC5A and CLEC2 in human platelet and neutrophil were determined by flow cytometry.



Supplementary Figure 2. Ultrastructure of DV-activated platelets-derived MVs and EXOs. Ultrastructure was observed under transmission electron microscopy. Scale bar: $0.1 \mu m$



Supplementary Figure 3. Immunofluorescence staining of the NET structure in spleen of DVchallenged mice. *Stat1^{-/-}* and *stat1^{-/-}clec5a^{-/-}* mice were inoculated with DV (NGC-N, 2x10⁵ PFU) via intraperitoneal route. Spleens were harvested and fixed at day 5 post-infection for immunofluorescence staining using anti-MPO mAb (red), anti-histone mAb (green), and Hoechst 33342 (blue). Scale bar: 10 μ m



Supplementary Figure 4. DNase I injection rescues the survival rate in DV-challenged *stat1*-/- mice. *Stat1*-/- mice (left panels) and *stat1*-/- *clec5a*-/- mice) (right panels) were challenged with lethal dose of DV via intraperitoneal route. DNase I (4 KU) were injected intraperitoneally at day 0, 2, 4, and 6 post infection. Survival rate was measured every day till day 21 post-infection.



Supplementary Figure 5. Gating strategy for platelet population and CD41⁺ EVs. Gating strategy for human/mouse platelets and CD41+ EVs for Fig. 1a, and Fig. 3a.

Supplementary Table 1

	Protein name	Gene name	Increase/ Decrease	Significantly different compared to mock (Score)
MVs	Tubulin beta-1 chain	TUBB1	¢	28.166
	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-3	GNG3	¢	6.0121
	Tribbles homolog 1	TRIB1	↑	5.8874
EXOs	Vinculin	VCL	1	21.874
	Coagulation factor XIII A chain	F13A1	↑	18.076
	Calnexin	CANX	\uparrow	11.591

Supplementary Table 1. Mass spectrometry analysis of aggretin- and DV-activated plateletsderived MVs and EXOs. Proteomic comparison of MVs and EXOs from resting platelets and CLEC2-activated platelets by LTQ Orbitrap XL mass spectrometer. Unique proteins which up expressed in CLEC2-MVs and EXOs are listed.